Abstract: The present invention refers to a process for production of a mixture including 2,4-furandicarboxylic acid (2,4-FDCA) and 2,5 furandicarboxylic acid (2,5-FDCA) through the disproportionation route, using as base compounds oxidation products of furfural. This invention also relates to a process for production of 2,4-FDCA as a result of a disproportionation route and the use of 2,4-FDCA as a monomer or comonomer to synthesize esters or any compounds which can generate macromolecules, such as polyesters.

Abstract: The invention relates to a lignocellulose preservative composition comprising in the range of from 50 to 98 wt % of a pyrolysis oil obtainable by pyrolysis of lignocellulosic material, a polymerisable furan compound and a catalyst for polymerising the furan compound in a catalytically effective amount. The invention further relates to a process for producing preserved lignocellulosic material comprising impregnating lignocellulosic material by immersion in such composition and subsequently curing the impregnated material and to preserved lignocellulosic material obtainable by such process and to an engineered wood or non-wood product comprising such lignocellulosic material.

Abstract: The invention relates to an apparatus for fast and homogeneously heating a liquid product to a heating temperature by means of resistive heating, the apparatus comprising at least two vertically mounted, longitudinal, heating chambers that are arranged in series.

Abstract: The invention is directed to methods for optimizing glycan processing in organisms (and in particular, plants) so that a glycoprotein having complex type bi-antennary glycans and thus containing galactose residues on both arms and which are devoid of (or reduce in) xylose and fucose can be obtained. The invention is further directed to said glycoprotein obtained and host system comprising said protein.

Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these. The invention provides a plant comprising functional mammalian ?1,4-galactosyltransferase and mammalian sialyl transferase for producing complex N-linked glycans that are galactosylated and sialylated, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

Abstract: The expression vector includes: the nucleic acids coding for the polypeptides forming a polypeptide complex having an enzyme activity allowing acetoacetyl-CoA to be converted to acetoacetate; optionally, at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetoacetate to be converted to acetone; and at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetone to be converted to isopropanol; the expression of the nucleic acids being controlled by a single constitutive promoter located upstream of the abovementioned nucleic acids.

Abstract: The present invention relates to non-mammalian ?-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian ?-1,4-galactosyltransferase and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation. The invention additionally provides nucleic acid molecules and expression vectors of non-mammalian ?-1,4-galactosyltransferases.

Abstract: The present invention provides materials and methods for DNA amplification, in particular linear amplification methods using RNA polymerase. These methods permit high-throughput sequencing of pictogram amounts of DNA and are of use in a range of applications including genome-wide profiling of transcription factors and epigenetic DNA and histone modifications, global transcript profiling, mapping of chromatin conformations, as well as for forensic use and archaeological studies.

Abstract: Described are Streptococcus suis infections in pigs, vaccines directed against those infections and tests for diagnosing S. suis infections. Provided is an isolated or recombinant nucleic acid encoding a capsular gene cluster of S. suis or a gene or gene fragment derived therefrom. Further provided is a nucleic acid probe or primer allowing species or serotype-specific detection of S. suis. Also provided is a Streptococcus suis antigen and vaccine derived therefrom.

Abstract: Serratia plymuthica strain A30, BCCM Deposit No. LMG P-26170, its analogues or functionally equivalent strains thereto, provides a biological control agent against plant disease caused by a bacterial pathogen, particularly a soft rot, e.g. blackleg. The pathogen is Dickeya spp., Pectobacterium spp., and Ralstonia spp.; including Dickeya sp. biovar 3 strain. The deposited strain and its variants are formulated in an agriculturally or horticulturally acceptable diluent, carrier, filler or adjuvant. Plants or plant parts, particularly potato tubers, containing the deposited strain provide useful propagation material free of soft rot or blackleg disease.

Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

Abstract: The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles.

Abstract: Described are antibodies specifically directed against a cathepsin-like protease that are specific for newly excysted juvenile (NEJ) stages of Fasciola hepatica. Diagnostic tests wherein such antibodies are detected or used are also provided.

Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

Abstract: The invention relates to control of pathogen caused diseases on leaves, fruits and ears in plants, such as apple scab (Venturia inaequalis by treatment of plant with an isolate of Cladosporium cladosporioides. The treatment is effective in both prevention and treatment of the fungal infection.

Abstract: This invention provides a novel means of predicting plant phenotypes that incorporates previously unusable dense marker data derived from historical pedigrees. The method operates by collecting information from a population pertaining to one or more loci, which is used to build one or more matrices by calculating, for the alleles present at the measured loci, the probability that the alleles are identical by descent. These matrices are then used to develop a second set of one or more matrices in which each value represents the probability that a certain individual in the population descended from a certain ancestral (founder) genotype. This set of second matrices can then be used as part of a breeding program for selecting and breeding individuals from the population or can be used to better classify the individuals in the population, leading to improved plant phenotypes.

Abstract: The invention relates to a process for the combined production of butanol and hydrogen from biomass, comprising the steps of fermenting biomass to obtain butanol in a first reaction mixture; removing the butanol and hydrogen from the first reaction mixture to obtain effluent; and using the effluent as a substrate in a second reaction mixture in a process using low substrate concentrations, in particular a hydrogen production process. Preferably, the process using low substrate concentrations is a hydrogen production process and at least part of the end products of the hydrogen production process is removed from the second reaction mixture for obtaining an effluent that comprises organic acid, which effluent is returned to the first reaction mixture.

Abstract: The invention relates to control of pathogen caused diseases on leaves, fruits and ears in plants, such as apple scab (Venturia inaequalis by treatment of plant with an isolate of Cladosporium cladosporioides. The treatment is effective in both prevention and treatment of the fungal infection.

Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.

Abstract: The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.